The latest from DatChem.
Media features, milestones and the science behind better, earlier detection.
DatChem news.
9News · Early Detection feature on DatChem
DatChem selected for the MedTech Global Accelerator.
DatChem is one of eight companies selected for Brisbane's flagship MedTech Global Accelerator, delivered by Brisbane Economic Development Agency in partnership with Life Science Nation. The program supports commercialisation and global partnerships, culminating in an investor pitch at J.P. Morgan Healthcare Week in San Francisco.
via Brisbane Economic Development Agency
DatChem wins top prize for women's health innovation.
At the 2026 Global Innovation in Women's Health Pitch Showcase, DatChem took the top award for its work detecting breast and ovarian cancer earlier, on the MRI scanners already in clinics. Co-founder and CEO Carolyn Mountford accepted the prize.
via Potomac24
Recent milestones.
Siemens Healthineers LOI signed
A letter of intent to launch DatChem products on Siemens MRI systems formalises a relationship 25 years in the making.
Longitudinal breast study completed
A 12-year validation study reports 30 of 31 cancers correctly predicted in the high-risk cohort, all on the very first scan.
PTSD & blast trial completed
A clinical trial funded by the USA CTTSO records up to five dysfunctional neural pathways, an objective first.
On track for FDA approval
With clinical sites in Australia and Europe, DatChem is on track for FDA, TGA and EMA approval.
ADHD trial on the horizon
Building on the PTSD breakthrough, an ADHD clinical trial is next, beginning in Australia with global intent.
Portfolio grows across three regions
Nine granted patents and twelve registered applications now span the US, EU and Australia.
Following the DatChem story?
For media, clinical or partnership enquiries, our team would be glad to help.